{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:18:35Z","timestamp":1790605115572,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute exacerbation of rheumatoid arthritis\u2013associated interstitial lung disease (AE-RA-ILD) is a life-threatening condition for which no standard therapy has been established. Although Janus kinase (JAK) inhibitors are effective for treating rheumatoid arthritis (RA) and have shown potential benefit in chronic RA-ILD, evidence supporting their use in AE-RA-ILD remains extremely limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included consecutive patients hospitalized for AE-RA-ILD who received JAK inhibitors alongside systemic glucocorticoids between January and December 2024. Clinical characteristics, laboratory data, treatment regimens, and outcomes were extracted from medical records. High-resolution computed tomography images were quantitatively evaluated at three time points\u2014before acute exacerbation (AE), at exacerbation onset, and after treatment\u2014using a standardized computed tomography (CT) scoring system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six patients with AE-RA-ILD were included. In five of the six cases, the JAK inhibitor was discontinued due to an adverse event prior to AE onset, with a median interval of 9 days between discontinuation and AE onset. Upadacitinib was administered to four patients, and baricitinib to two patients. Three patients received methylprednisolone pulse therapy. Respiratory status improved in all patients, as indicated by increases in the PaO\n                      <jats:sub>2<\/jats:sub>\n                      \/FiO\n                      <jats:sub>2<\/jats:sub>\n                      ratio. The total CT score increased from baseline (175.3 \u00b1 50.3) to AE onset (247.2 \u00b1 53.6) and subsequently decreased after treatment (220.1 \u00b1 58.6), with notable improvement in fibrotic lesion components. All patients survived during the 3-month observation period, although four patients experienced a decline in percent predicted forced vital capacity, and three required home oxygen therapy at discharge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective case series, adjunctive treatment with JAK inhibitors was associated with improvements in respiratory status and radiological findings in patients with AE-RA-ILD. These findings suggest that JAK inhibitors may represent a promising therapeutic option for this severe condition and support the need for further investigation in larger, prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1800161","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:43:53Z","timestamp":1776059033000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Janus kinase inhibitors in the treatment of acute exacerbations of rheumatoid arthritis\u2013associated interstitial lung disease: a retrospective observational case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Momoko","family":"Okamoto","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital","place":["Isahaya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital","place":["Isahaya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomo","family":"Mihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japan Community Healthcare Organization, Isahaya General Hospital","place":["Isahaya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japan Community Healthcare Organization, Isahaya General Hospital","place":["Isahaya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tomari","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japan Community Healthcare Organization, Isahaya General Hospital","place":["Isahaya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kido","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriho","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Mizokami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital","place":["Isahaya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/09059180.00008014","article-title":"Rheumatoid arthritis-associated lung disease","volume":"24","author":"Shaw","year":"2015","journal-title":"Eur Respir Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-022-01978-y","article-title":"Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model","volume":"23","author":"Hozumi","year":"2022","journal-title":"Respir Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1173816","article-title":"Efficacy\u00a0of\u00a0intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease","volume":"27","author":"Ota","year":"2017","journal-title":"Mod Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.07.008","article-title":"Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database","volume":"51","author":"Nakamura","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25248","article-title":"2023 American College of Rheumatology\/American College of Chest Physicians guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/jcm12030957","article-title":"Evolution of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a retrospective exploratory study","volume":"12","author":"Venerito","year":"2023","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005062","article-title":"Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study","volume":"11","author":"Triboulet","year":"2025","journal-title":"RMD Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1501146","article-title":"Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients","volume":"15","author":"Kurushima","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41584-021-00712-0","article-title":"Acute exacerbation of interstitial lung disease associated with rheumatic disease","volume":"18","author":"Luppi","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur Respir J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000545","article-title":"Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency","volume":"2","author":"Ichikado","year":"2012","journal-title":"BMJ Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914509","article-title":"Etiology and pathogenesis of rheumatoid arthritis-interstitial lung disease","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12890-023-02532-2","article-title":"Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis","volume":"4","author":"Tvorogov","year":"2018","journal-title":"Sci Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311706","article-title":"JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events","volume":"20","author":"Gurevic","year":"2025","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00443-0","article-title":"Enhancing outcomes in chronic fibrotic interstitial lung disease through aggressive management of nintedanib-induced adverse drug reactions","volume":"11","author":"Chang","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"B21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s40001-023-01384-0","article-title":"Clinical significance of interleukin-6, total bilirubin, and CD3+CD4+ T cell counts in acute exacerbation of connective tissue disease-associated interstitial lung disease","volume":"28","author":"Ma","year":"2023","journal-title":"Eur J Med Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13075-024-03415-5","article-title":"Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease","volume":"26","author":"Niu","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173806","article-title":"Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Yamakawa","year":"2021","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2023.2274707","article-title":"Resolution of exacerbated rheumatoid arthritis-associated interstitial lung disease under baricitinib treatment","volume":"53","author":"Komai","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00330-011-2211-6","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality","volume":"22","author":"Fujimoto","year":"2012","journal-title":"Eur Radiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.42719","article-title":"The risk of lung cancer in rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease","volume":"76","author":"Brooks","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:43:54Z","timestamp":1776059034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1800161"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1800161","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1800161"}}